Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?
作者信息
Solanich X, Padullés N, Niubó J, Videla S, Antolí A, Rocamora-Blanch G, Corbella X
机构信息
From the, Department of Internal Medicine, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Pharmacy, Bellvitge University Hospital, Bellvit, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
出版信息
J Intern Med. 2021 Jun;289(6):926-927. doi: 10.1111/joim.13264. Epub 2021 Feb 25.
Abstract
摘要
相似文献
1
Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?使用钙调神经磷酸酶抑制剂抑制新型冠状病毒 2 型复制：临床所需浓度是否可实现？
J Intern Med. 2021 Jun;289(6):926-927. doi: 10.1111/joim.13264. Epub 2021 Feb 25.
2
Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable?致编辑的回信：使用钙调神经磷酸酶抑制剂抑制新型冠状病毒2（SARS-CoV-2）复制：临床所需浓度是否可实现？
J Intern Med. 2021 Jun;289(6):928-929. doi: 10.1111/joim.13278. Epub 2021 Apr 6.
3
Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling.Nsp1 通过钙调神经磷酸酶-NFAT 信号促进 SARS-CoV-2 复制。
mBio. 2024 Apr 10;15(4):e0039224. doi: 10.1128/mbio.00392-24. Epub 2024 Feb 27.
4
The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture.环孢素 D 依赖性钙调神经磷酸酶抑制剂伏环孢素抑制细胞培养中的 SARS-CoV-2 复制。
Transpl Int. 2022 Jun 24;35:10369. doi: 10.3389/ti.2022.10369. eCollection 2022.
5
Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).环孢素抑制剂阿利匹韦（Debio 025）抑制 SARS-CoV-2 感染。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00876-20.
6
Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.环孢素同时抑制 SARS-CoV-2 的进入途径。
ACS Chem Neurosci. 2021 Mar 3;12(5):930-944. doi: 10.1021/acschemneuro.1c00019. Epub 2021 Feb 19.
7
Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection.环孢素作为新冠病毒感染的肾移植受者首选的钙调神经磷酸酶抑制剂。
Kidney Int. 2020 Aug;98(2):507-508. doi: 10.1016/j.kint.2020.05.024. Epub 2020 Jun 4.
8
Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.用于高通量抗病毒筛选和测试的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）报告基因复制子的构建
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15). doi: 10.1073/pnas.2025866118.
9
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.蛋白酶抑制剂：抑制严重急性呼吸综合征冠状病毒 2 复制的候选药物。
Tohoku J Exp Med. 2020 May;251(1):27-30. doi: 10.1620/tjem.251.27.
10
Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.干扰素-β-1a 对病毒感染后给药时体外严重急性呼吸综合征冠状病毒 2 的抑制作用。
J Infect Dis. 2020 Aug 4;222(5):722-725. doi: 10.1093/infdis/jiaa350.
引用本文的文献
1
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.环孢素 A 通过三种 SARS-CoV-2 变体抑制肺细胞中的病毒感染和释放以及细胞因子产生。
Microbiol Spectr. 2022 Feb 23;10(1):e0150421. doi: 10.1128/spectrum.01504-21. Epub 2022 Jan 5.
2
Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial.环孢素联合法匹拉韦治疗地塞米松治疗反应不佳的重症 COVID-19 患者：一项非对照前瞻性试验。
Int Immunopharmacol. 2021 Oct;99:108043. doi: 10.1016/j.intimp.2021.108043. Epub 2021 Aug 4.
3
Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial.在重症新型冠状病毒肺炎患者中，甲泼尼龙冲击联合他克莫司加标准治疗与单纯标准治疗的比较：一项随机对照试验
Front Med (Lausanne). 2021 Jun 14;8:691712. doi: 10.3389/fmed.2021.691712. eCollection 2021.
Zotero 插件